Autosomal recessive ataxia (ARCA) is a complex group of progressive neurodegenerative disorders that mostly occurs in childhood. Ataxia with ocular apraxia type 1 (AOA1) is a relatively rare form of ARCA caused by a variant in the APTX gene on chromosome 9p13.3. Reference da Costa, Rezende Filho Fávio and de Freitas Júlian1 AOA1 is characterized by cognitive dysfunction, ataxia with cerebellar atrophy, ocular motor apraxia (OMA), dystonia, and peripheral neuropathy, accompanied by hypercholesterolemia and hypoalbuminemia.
The patient, a 21-year-old male, initially presented at the age of 15 years with swaying of the body from side to side during daily activities and was unable to walk in a straight line. At the age of 20 years, the patient was hobbling and swaying while walking, with wider foot distances and a tendency to fall. Meanwhile, he had slurred speech and poor fluency. On admission, bilateral horizontal nystagmus was detected in the patient. His speech was slurred and he walked unsteadily with a broad-based gait. Capillary dilatation and muscle atrophy were not presented. Besides, the Medical Research Council (MRC) scale score for the strength in extremities is 5-/5, decreased muscle tone and tendon reflexes (+) were detected. Moreover, the patient was dysmetric in the bilateral finger–nose and heel–shin–knee tests. The rebound (Stewart–Holmes) and Romberg tests were also positive.
The patient’s parents are consanguineous (first cousins), and he has a younger sister. Both his parents and sister are healthy.
The laboratory examination revealed that total protein decreased to 53.3 g/L (65–85 g/L) and albumin decreased to 31.2 g/L (40–55 g/L). In addition, the patient scored 30 points on the Mini-mental State Examination (MMSE) (a total of 30 points).
Brain magnetic resonance imaging (MRI) detected cerebellar atrophy without involvement of the brainstem or cerebral cortex (Figure 1A).
(A) MRI images of the patient. Sagittal T2 cranial MRI, T1, T2 axial images display diffuse cerebellar atrophy. (B) Genetic sequencing of patients and their parents: The patient had one A > C homozygous missense mutation (c.793 A > C) at the c.793 locus in the exon 7 region of the APTX gene. The mutation caused the mutation of amino acid 265 from serine to arginine (as shown by the arrow in panel a). His father and mother were each found to have the same heterozygous missense mutation as the patient (as shown by the arrow in panels b,c). (C) Clinical and genetic data on the family. Genealogical spectrum of the AOA1 family. (Double lines indicate consanguineous marriages. Squares indicate male family members. Circles indicate female family members. Fully shaded symbols indicate AOA1 patients. Half-shaded symbols indicate autosomal recessive gene carriers. Open symbols indicate healthy members).

Through ataxia-focus next-generation sequencing panel and Sanger sequencing validation, it was confirmed that there was a homozygous variant in the exon 7 region of the patient’s APTX gene: c.793 A > C (p.S265R) (Figure 1B). This variant is a missense variant, which is a base variation from A to C at position 793 of the coding sequence in the APTX gene. As a result, the 265th amino acid encoded by the gene changed from S (serine) to R (arginine). Both parents carry the same variant locus as the patient (Figure 1C).
This variant is not included in the HGMD Pro, Esp6500, ClinVar, or ExAC database and occurs at a very low frequency in the population (PM2_P).
Pathogenicity of APTX gene variants was predicted using bioinformatics prediction software (SIFT, Polyphen2, MutationTaster, LR pred, and REVEL), and the results show that: REVEL: 0.934; “deleterious” (SIFT, Polyphen2, MutationTaster, LR pred) (PP3_S). In addition, the clinical phenotype of cerebellar ataxia in our patient was essentially matched to the disease phenotype associated with the gene. Furthermore, the variant is consistent with an autosomal recessive mode of inheritance (homozygous variant). For these reasons, the variant was categorized as a clinically significant unspecified variant that could explain the patient’s phenotype (ACMG:PM2_P /PP3_S).
The patient was treated with Coenzyme Q10 10 mg tid, Haloperidol 4 mg bid, and Idebenone 30 mg tid orally. After treatment, the patient’s symptoms improved slightly.
The APTX gene is located on chromosome 9p13.3 and encodes an Aprataxin protein that is a member of the histidine triad (HIT) superfamily. Reference Aguillon, Vasquez and Madrigal2 Aprataxin protein consists of three structural domains, HIT, FHA (an N-terminal forkhead-associated domain) and Znf (a C-terminal domain containing a divergent zinc-finger motif). Reference Ababneh, Ali and Al-Kurdi3 In our patient, a homozygous missense variant was found at locus 793 in exon 7 of the APTX gene, which is located in the HIT domain. It has been confirmed that missense variants located in the HIT domain can lead to destabilization of the APTX gene with copy number reduction and subcellular distribution changes from nucleolar to cytoplasmic distribution. Reference Balint, Rispoli and Latorre4 Therefore, combining the location and nature of the APTX gene variant in this patient, it is considered that this variant may cause structural changes in the protein from the HIT to the Znf structural domains. It affects the effective removal of Adenosine Monophosphate (AMP) molecules at the ends of DNA strands, leading to impaired repair of SSBs, which in turn disrupts genome integrity and reduces cell viability. However, it is worth noting that due to the limited sample size in this study, the exact effect of the different positions of the variants in the HIT structural domain on the protein function still needs to be further verified in future biological experiments.
There is strong clinical heterogeneity in AOA1, and it is difficult to establish a precise relationship between genotype and phenotype. Reference Renaud, Moreira and Ben Monga5 Our patient’s symptoms started at the age of 15 years and gradually suffered from cerebellar ataxia, including dysarthria and decreased muscle tone. He did not exhibit cognitive deficits, OMA, or hypercholesterolemia. Nonsense variants, code-shifting variants, and classical shear site variants in the APTX gene are thought to be the main cause of early onset of AOA1. Reference Brandsma, Verschuuren-Bemelmans and Amrom6 The patient had a homozygous missense mutation with a new variant site c.793A > C. It cannot be excluded that this variant type and site are closely related to the occurrence of late-onset AOA1. OMA is a prominent ocular change in AOA1, but it is undeniable that OMA is likely to be a landmark manifestation late in the course of AOA1. Reference Lopergolo, Rosini and Pretegiani7 In this study, the patient has a course of 6 years so far and will need to be monitored closely for any ocular changes in the future.
In conclusion, this study reports a rare case of late-onset AOA1, and the discovery of a novel homozygous missense variant site (c.793 A > C) extends the genotypic spectrum of AOA1. This patient had a late-onset disease, presented with cerebellar ataxia, without cognitive deficits and OMA. We emphasized the clinical heterogeneity of AOA1 and further explored the genotype–phenotype correlation of AOA1. However, it must be acknowledged that this research is a case study of a single patient and is limited in drawing broad conclusions.
Data availability statement
The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.
Acknowledgments
This study is not a clinical trial. This article belongs to a case report. We sincerely thank the patient and the family for their help in this study.
Funding statement
This work was supported by the General program of Anhui Natural Science Foundation (2208085MH271), The General Program of the National Natural Science Foundation of China (81973825), Anhui Province Traditional Chinese Medicine Inheritance and Innovation Research Project (2024CCCX093), Anhui Province Higher Education Science Research Major Project (2024AH040153) and Anhui Province Higher Education Science Research Key Project (2024AH051016).
Competing interests
All authors report no relevant conflicts of interest/financial disclosures.
Author contribution
ZZ S, S J and X F: drafting/revision of the manuscript for content, including medical writing for content.
WM Y: major role in the acquisition of data.
The final draft was read and approved by all the authors.
Ethics approval statement
This study was approved by the Ethics Committee of The First Affiliated Hospital of Anhui University of Chinese Medicine (batch number: 2021AH-60). The patient and her relatives were informed and provided written consent for the study and the publication of this report.
